


Supplementary Materials

This document gives supplementary information for the manuscript titled “The influence of genetic predisposition and physical activity on risk of Gestational Diabetes Mellitus in the nuMoM2b cohort” by Pagel, Chu, Ramola, *et al.*, 2022.


Selection of METs thresholds



Supplementary Figure S1. The p-value of GDM incidence for the METs-based subgroups. The cohort was split based on the METs threshold shown on the x-axis and the two-sample t-test p-value, shown on the y-axis, was calculated using the binary vectors of the incidence of GDM in each group (1 = cases, 0 = controls). The yellow (METs = 256) and green (METs = 1650) dashed lines show the lowest and the largest METs value with a p-value below 0.05. The red dashed line shows the METs value (METs = 491) with the strongest separation between the two groups, based on the p-value.


Inferred European Participants

Subgroup	Cases	Controls	OR	95% CI	P	LR ⁺	95% CI	P	P*
Family DM History	47	631	2.3	(1.6, 3.3)	1.91 · 10 ⁻⁵	1.9	(1.4, 2.3)	<0.001	
+PRS Bottom 25%	10	138	1.9	(1.0, 3.7)	0.075	1.8	(0.8, 3.1)	0.083	0.420
+PRS Top 25%	16	182	2.4	(1.4, 4.1)	0.004	2.2	(1.2, 3.3)	0.008	0.223
+METs<450	25	229	3.1	(2.0, 4.9)	7.66 · 10 ⁻⁶	2.7	(1.8, 3.8)	<0.001	0.015
+METs≥450	22	402	1.4	(0.9, 2.3)	0.138	1.4	(0.9, 1.9)	0.087	0.015
Age>35	37	346	3.3	(2.2, 4.8)	4.51 · 10 ⁻⁸	2.7	(2.0, 3.5)	<0.001	
+PRS Bottom 25%	7	92	2.0	(0.9, 4.3)	0.103	1.9	(0.6, 3.5)	0.118	0.103
+PRS Top 25%	15	83	5.0	(2.8, 8.8)	3.20 · 10 ⁻⁶	4.5	(2.5, 7.2)	<0.001	0.025
+METs<450	17	101	4.7	(2.7, 8.0)	1.62 · 10 ⁻⁶	4.2	(2.4, 6.6)	<0.001	0.025
+METs≥450	20	245	2.2	(1.4, 3.6)	0.003	2.0	(1.3, 3.0)	0.003	0.025
BMI>25	93	1455	2.7	(1.9, 3.9)	1.01 · 10 ⁻⁸	1.6	(1.4, 1.8)	<0.001	
+PRS Bottom 25%	15	370	1.0	(0.6, 1.8)	0.889	1.0	(0.6, 1.5)	<0.001	0.009
+PRS Top 25%	37	353	3.2	(2.2, 4.7)	7.34 · 10 ⁻⁸	2.6	(1.9, 3.5)	<0.001	0.002
+METs<450	42	552	2.3	(1.6, 3.3)	3.41 · 10 ⁻⁵	1.9	(1.4, 2.4)	<0.001	0.079
+METs≥450	51	903	1.6	(1.2, 2.3)	0.006	1.4	(1.1, 1.8)	0.003	0.078



Supplementary Figure S2. Influence of PRS and METs on the GDM risk in the context of key clinical covariates (Family DM History, age, and BMI). The cases and controls list the number of participants in a subgroup on the left. The OR and LR⁺ values reflect the risk of developing GDM among subgroup participants with the rest of the cohort used as the reference group for OR and the entire cohort for LR⁺. OR p-value (*P*) was determined using Fisher's exact test. LR⁺ p-value (*P*) is the bootstrapped p-value of the LR⁺, where the reference group is all participants. LR⁺ p-value against parent subgroup (*P**) is the bootstrapped p-value of the LR⁺, where the reference group is the parent subgroup only.


Subgroup	Cases	Controls	OR	95% CI	P	LR ⁺	95% CI	P	P*
PRS Bottom 25%	23	910	0.6	(0.4, 0.9)	0.010	0.6	(0.4, 0.9)	0.002	
+METs<450	9	287	0.8	(0.4, 1.5)	0.634	0.8	(0.3, 1.3)	0.186	0.216
+METs≥450	14	623	0.5	(0.3, 0.9)	0.017	0.6	(0.3, 0.8)	0.002	0.217
PRS Top 25%	60	874	2.2	(1.6, 3.2)	7.02 · 10 ⁻⁴	1.7	(1.4, 2.1)	<0.001	
+METs<450	33	297	3.3	(2.2, 5.0)	1.29 · 10 ⁻⁷	2.8	(2.0, 3.8)	<0.001	<0.001
+METs≥450	27	577	1.2	(0.8, 1.9)	0.356	1.2	(0.8, 1.6)	0.189	<0.001
METs≥450	82	2405	0.7	(0.5, 0.9)	0.018	0.9	(0.7, 1.0)	0.016	0.016
+PRS Bottom 25%	14	623	0.5	(0.3, 0.9)	0.017	0.6	(0.3, 0.8)	0.002	0.016
+PRS Top 25%	27	577	1.2	(0.8, 1.9)	0.356	1.2	(0.8, 1.6)	0.189	0.051
METs<450	61	1185	1.5	(1.1, 2.1)	0.018	1.3	(1.0, 1.5)	0.016	0.016
+PRS Bottom 25%	9	287	0.8	(0.4, 1.5)	0.634	0.8	(0.3, 1.3)	0.186	0.019
+PRS Top 25%	33	297	3.3	(2.2, 5.0)	1.29 · 10 ⁻⁷	2.8	(2.0, 3.8)	<0.001	<0.001



Supplementary Figure S3. Cooperative effects of PRS and METs on GDM risk. The cases and controls list the number of participants in a subgroup on the left. The OR and LR⁺ values reflect the risk of developing GDM among subgroup participants with the rest of the cohort used as the reference group for OR and the entire cohort for LR⁺. OR p-value (*P*) was determined using Fisher's exact test. LR⁺ p-value (*P*) is the bootstrapped p-value of the LR⁺, where the reference group is all participants. LR⁺ p-value against parent subgroup (*P**) is the bootstrapped p-value of the LR⁺, where the reference group is the parent subgroup only.


Self-Reported White Participants

Subgroup	Cases	Controls	OR	95% CI	P	LR ⁺	95% CI	P	P*
Family DM History	47	663	2.4	(1.7, 3.4)	9.19 · 10 ⁻⁶	1.9	(1.5, 2.4)	<0.001	
+PRS Bottom 25%	9	145	1.7	(0.9, 3.4)	0.122	1.7	(0.7, 2.9)	0.097	0.319
+PRS Top 25%	17	195	2.5	(1.5, 4.3)	0.002	2.3	(1.3, 3.5)	0.028	0.175
+METs<450	24	235	3.1	(2.0, 4.9)	1.09 · 10 ⁻⁵	2.7	(1.8, 3.9)	0.001	0.018
+METs≥450	23	428	1.5	(1.0, 2.4)	0.078	1.4	(0.9, 2.0)	0.054	0.018
Age>35	34	376	2.9	(1.9, 4.3)	1.61 · 10 ⁻⁶	2.4	(1.7, 3.2)	<0.001	
+PRS Bottom 25%	6	99	1.7	(0.7, 3.8)	0.276	1.6	(0.5, 3.2)	0.170	0.119
+PRS Top 25%	14	86	4.8	(2.6, 8.6)	9.47 · 10 ⁻⁶	4.4	(2.3, 7.1)	<0.001	0.017
+METs<450	15	104	4.2	(2.4, 7.5)	1.66 · 10 ⁻⁵	3.9	(2.1, 6.2)	<0.001	0.033
+METs≥450	19	272	2.0	(1.2, 3.3)	0.008	1.9	(1.1, 2.8)	0.012	0.033
BMI>25	91	1497	2.8	(2.0, 4.0)	3.58 · 10 ⁻⁹	1.6	(1.4, 1.8)	<0.001	
+PRS Bottom 25%	13	377	0.9	(0.5, 1.6)	0.886	0.9	(0.5, 1.5)	0.379	0.004
+PRS Top 25%	36	371	3.2	(2.1, 4.7)	1.27 · 10 ⁻⁷	2.6	(1.9, 3.4)	<0.001	0.002
+METs<450	42	551	2.5	(1.7, 3.6)	5.70 · 10 ⁻⁶	2.0	(1.5, 2.6)	<0.001	0.043
+METs≥450	49	946	1.6	(1.1, 2.3)	0.010	1.4	(1.1, 1.7)	0.007	0.043



Supplementary Figure S4. Influence of PRS and METs on the GDM risk in the context of key clinical covariates (Family DM History, age, and BMI). The cases and controls list the number of participants in a subgroup on the left. The OR and LR⁺ values reflect the risk of developing GDM among subgroup participants with the rest of the cohort used as the reference group for OR and the entire cohort for LR⁺. OR p-value (*P*) was determined using Fisher's exact test. LR⁺ p-value (*P*) is the bootstrapped p-value of the LR⁺, where the reference group is all participants. LR⁺ p-value against parent subgroup (*P*^{*}) is the bootstrapped p-value of the LR⁺, where the reference group is the parent subgroup only.

Subgroup	Cases	Controls	OR	95% CI	P	LR ⁺	95% CI	P	P*
PRS Bottom 25%	21	948	0.5	(0.3, 0.8)	0.005	0.6	(0.4, 0.8)	0.001	
+METs<450	9	288	0.8	(0.4, 1.6)	0.744	0.8	(0.4, 1.5)	0.286	0.129
+METs≥450	12	660	0.4	(0.2, 0.8)	0.004	0.5	(0.2, 0.8)	<0.001	0.129
PRS Top 25%	57	913	2.2	(1.5, 3.0)	2.39 · 10 ⁻⁵	1.7	(1.3, 2.0)	<0.001	
+METs<450	32	302	3.4	(2.3, 5.1)	1.20 · 10 ⁻⁷	2.8	(2.0, 3.8)	<0.001	<0.001
+METs≥450	25	611	1.1	(0.7, 1.7)	0.640	1.1	(0.7, 1.5)	0.313	<0.001
METs≥450	79	2542	0.6	(0.4, 0.9)	0.007	0.8	(0.7, 1.0)	0.005	
+PRS Bottom 25%	12	660	0.4	(0.2, 0.8)	0.004	0.5	(0.2, 0.8)	<0.001	0.007
+PRS Top 25%	25	611	1.1	(0.7, 1.7)	0.640	1.1	(0.7, 1.5)	0.313	0.073
METs<450	60	1195	1.6	(1.1, 2.3)	0.007	1.3	(1.1, 1.6)	0.005	
+PRS Bottom 25%	9	288	0.8	(0.4, 1.6)	0.744	0.8	(0.4, 1.5)	0.281	0.039
+PRS Top 25%	32	302	3.4	(2.3, 5.1)	1.20 · 10 ⁻⁷	2.8	(2.0, 3.8)	<0.001	<0.001



Supplementary Figure S5. Cooperative effects of PRS and METs on GDM risk. The cases and controls list the number of participants in a subgroup on the left. The OR and LR⁺ values reflect the risk of developing GDM among subgroup participants with the rest of the cohort used as the reference group for OR and the entire cohort for LR⁺. OR p-value (*P*) was determined using Fisher's exact test. LR⁺ p-value (*P*) is the bootstrapped p-value of the LR⁺, where the reference group is all participants. LR⁺ p-value against parent subgroup (*P**) is the bootstrapped p-value of the LR⁺, where the reference group is the parent subgroup only.